Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) generates news flow typical of clinical-stage biotechnology companies pursuing FDA approval for novel treatments. As a dermatology and immunology-focused biotech, news coverage centers on clinical trial milestones, regulatory interactions, and pipeline advancement.
Clinical trial updates represent the most significant news events for Aclaris. Phase 1, Phase 2, and Phase 3 trial initiations signal pipeline progression, while data readouts from completed studies often drive substantial investor interest. Positive efficacy results can validate the company's therapeutic approach, while safety data informs the risk-benefit profile of drug candidates.
Regulatory news includes FDA designation announcements, meeting outcomes, and submission updates. Fast Track or Breakthrough Therapy designations indicate FDA recognition of a drug's potential to address unmet medical needs. These designations can accelerate development timelines and generate investor attention.
Conference presentations at medical and investor conferences provide visibility into Aclaris's scientific progress. Late-breaking abstracts accepted at dermatology or immunology conferences signal noteworthy research findings. Investor conference participation offers management perspectives on corporate strategy and pipeline priorities.
Corporate developments include leadership appointments, financing transactions, and partnership announcements. For clinical-stage companies, cash position updates and equity offerings inform operational runway estimates. Strategic partnerships or licensing deals can validate pipeline assets and provide non-dilutive funding.
Quarterly earnings reports summarize financial position, R&D spending, and clinical progress. These reports contextualize cash burn rates against development timelines and upcoming catalysts.
Bookmark this page to follow Aclaris Therapeutics news as the company advances its dermatology and immunology pipeline through clinical development.
Aclaris Therapeutics (NASDAQ: ACRS) announced positive top-line results from its Phase 2a trial of ATI-2138, an oral inhibitor targeting ITK and JAK3, for atopic dermatitis treatment. The trial met its primary endpoint, demonstrating a favorable safety profile with no severe adverse events.
Key efficacy results showed a 60.5% mean improvement in EASI score at week 12, reaching 77.1% when excluding one outlier patient. Additionally, 62.5% of patients achieved significant itch reduction. The drug demonstrated strong pharmacodynamic results, with 90% ITK target occupancy at peak and significant downregulation of inflammatory markers.
Based on these results, Aclaris plans to advance ATI-2138's development for alopecia areata and explore additional indications. The company is also developing next-generation ITK inhibitors, with new INDs expected in 2026.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, has announced a significant leadership transition in its scientific team. Roland Kolbeck, Ph.D. has been appointed as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role through Q1 2026 as part of his planned retirement.
Dr. Kolbeck brings nearly 30 years of senior R&D leadership experience, most recently serving as CSO at Spirovant Sciences. His notable achievements include his role as VP and Head of Respiratory, Inflammation and Autoimmune Research at MedImmune, where six monoclonal antibodies from his portfolio received FDA approval. The transition comes as Aclaris continues to develop its portfolio of immuno-inflammatory product candidates, including next-generation kinase inhibitors and first-in-class bispecific antibodies.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.
The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.
Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in June 2025. The company's CEO Dr. Neal Walker and senior leadership team will participate in:
1. A fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 10:30 AM EDT
2. A fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami on June 11, 2025, at 1:20 PM EDT
Live webcasts of both events will be available on the Events page of Aclaris' website and will remain accessible for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the HC Wainwright "HCW@Home" virtual series. The company's CEO Neal Walker and senior leadership team will engage in a fireside chat scheduled for May 16, 2025, at 1:00 PM EDT. Investors and interested parties can access the live webcast and a 30-day replay through the Events page on the company's website at aclaristx.com.
Aclaris Therapeutics has appointed Jesse Hall, M.D. as Chief Medical Officer, strengthening its leadership in immuno-inflammatory disease therapeutics. Dr. Hall brings extensive experience in clinical development, particularly in immunology and antibody development.
Dr. Hall's previous role was CMO at AltruBio, and he has held positions at notable companies including Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen, and Abbott Labs. His track record includes work on successful monoclonal antibodies like HUMIRA and PROLIA.
As part of his employment package starting May 1, 2025, Dr. Hall will receive:
- 510,000 nonstatutory stock options
- 145,500 restricted stock units
These equity awards will vest over four years, with 25% vesting annually, subject to continued employment. The grants are part of Aclaris' 2024 Inducement Plan, designed for new employees under Nasdaq Rule 5635(c)(4).
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
